Myriad Genetics (NASDAQ:MYGN) had its price target lifted by research analysts at Barclays from $30.00 to $35.00 in a research report issued on Monday. The brokerage presently has an “equal weight” rating on the stock. Barclays’ target price would indicate a potential downside of 12.13% from the stock’s previous close.
Other equities analysts also recently issued research reports about the company. ValuEngine upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Friday, November 10th. BTIG Research set a $41.00 target price on Myriad Genetics and gave the company a “buy” rating in a research report on Tuesday, January 16th. Stephens set a $45.00 target price on Myriad Genetics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 15th. Finally, Deutsche Bank raised their target price on Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Myriad Genetics presently has an average rating of “Hold” and an average price target of $30.55.
Myriad Genetics (NASDAQ:MYGN) traded up $1.21 during midday trading on Monday, hitting $39.83. The stock had a trading volume of 524,874 shares, compared to its average volume of 666,962. The stock has a market capitalization of $2,780.00, a P/E ratio of 26.91, a PEG ratio of 2.45 and a beta of 0.24. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $38.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34.
Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.05. The business had revenue of $190.20 million for the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.23 earnings per share. research analysts forecast that Myriad Genetics will post 1.05 EPS for the current fiscal year.
In other Myriad Genetics news, VP Gary A. King sold 3,120 shares of the firm’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $38.12, for a total transaction of $118,934.40. Following the completion of the sale, the vice president now owns 125,088 shares of the company’s stock, valued at $4,768,354.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Heinrich Dreismann sold 6,000 shares of the firm’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $33.50, for a total value of $201,000.00. Following the sale, the director now directly owns 33,743 shares of the company’s stock, valued at approximately $1,130,390.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,410 shares of company stock worth $1,163,524. 6.70% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the business. GHP Investment Advisors Inc. increased its stake in Myriad Genetics by 11.1% during the third quarter. GHP Investment Advisors Inc. now owns 48,710 shares of the company’s stock worth $1,762,000 after acquiring an additional 4,853 shares during the last quarter. Vanguard Group Inc. increased its stake in Myriad Genetics by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock worth $162,992,000 after acquiring an additional 56,708 shares during the last quarter. PDT Partners LLC acquired a new stake in Myriad Genetics during the second quarter worth $8,481,000. Shell Asset Management Co. increased its stake in Myriad Genetics by 34.3% during the third quarter. Shell Asset Management Co. now owns 54,867 shares of the company’s stock worth $2,116,000 after acquiring an additional 14,021 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in Myriad Genetics by 3.9% during the third quarter. Prudential Financial Inc. now owns 131,073 shares of the company’s stock worth $4,742,000 after acquiring an additional 4,900 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/22/barclays-raises-myriad-genetics-mygn-price-target-to-35-00.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.